PFIZER INC.

ASCO's annual meeting highlights include BMS's Opdivo/Yervoy combo showing promise in liver cancer, Sanofi's Sarclisa combo reducing multiple myeloma progression, BMS's Breyanzi efficacy in lymphoma, and AstraZeneca's Enhertu improving breast cancer PFS. Other notable updates include GSK's Blenrep in myeloma, AstraZeneca's Imfinzi in lung cancer, and Pfizer/Takeda's Adcetris in Hodgkin lymphoma.

The FDA approved Moderna's RSV vaccine, mResvia, for adults 60+, joining GSK and Pfizer's vaccines. RSV causes severe illness in vulnerable groups. Moderna's mRNA-based vaccine, with a prefilled syringe, aims to compete in a market expected to grow to $6-8 billion annually. Efficacy and safety are comparable among the vaccines, with ongoing research into broader eligibility and durability of protection.

The global infertility drugs market, valued at US$ 3.9 Billion in 2023, is projected to grow to US$ 6.0 Billion by 2032, with a CAGR of 4.90%. Growth is driven by rising infertility rates, public awareness, chronic health conditions, healthcare advancements, and generic drug demand. Key players include Abbott Laboratories, Bayer AG, and Ferring Pharmaceuticals.

John Mulcahy, CEO of SiteOne Therapeutics, notes pain treatment's recent industry resurgence. The company aims to use new funding to achieve 'proof of concept' for its pain medicines.

Pfizer's Q1 2024 earnings call highlighted a solid start to the year, with a focus on executing five strategic priorities: achieving world-class oncology leadership, delivering pipeline innovation, maximizing new product performance, expanding margins, and enhancing shareholder value. The company reported operational revenue growth of 11% excluding COVID products, with notable progress in oncology and other key areas. Pfizer also discussed its cautious optimism for the year ahead, emphasizing disciplined execution and strategic investments to drive growth and shareholder returns.

The Scope of Things podcast covers AI in drug repurposing for rare diseases, new breast cancer treatments, AutoCruitment's prescreening, placental pathology in trials, ethical oversight, and industry bias in psychiatric drug studies. It features insights from clinical research leaders and discussions from SCOPE Europe 2024.

In 2020, AstraZeneca's Covid vaccine was a global hope due to its cost and storage advantages, significantly aiding the UK's pandemic response. Despite saving over 6.5 million lives, rare blood clot side effects and the virus's evolution led to decreased demand, making the vaccine obsolete as updated versions became necessary.

The global clinical trials market is projected to grow from $55.2 billion in 2023 to $83.16 billion by 2030, at a CAGR of 6.03%. Growth is driven by technological advancements, precision medicine, and the increasing burden of diseases. North America leads due to high R&D expenditure and robust regulatory frameworks. Oncology dominates the indication segment, with Phase III trials holding the largest market share. Interventional studies lead by study material, fueled by the demand for improved diagnostics and vaccines.

The global clinical trials market is projected to grow from US$55.20 billion in 2023 to US$83.16 billion by 2030, at a CAGR of 6.03%. Growth is driven by technological advancements, precision medicine, and the increasing burden of diseases. North America leads due to high R&D expenditure and a robust regulatory framework. Phase III trials dominate, with oncology being the leading indication. Interventional studies are the most prevalent, fueled by the need for improved diagnostics and vaccines.

Pfizer's RSV vaccine Abrysvo showed promising immune response in higher risk adults under 60, similar to older adults. Pfizer plans to seek expanded approval for ages 18-59. GSK also aims to expand its RSV vaccine Arexvy's age range, with FDA decision expected by June 7. RSV is a major cause of pneumonia in toddlers and older adults.